Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: A meta-analysis

Urology

Volumn 82, Issue 2, 2013, Pages 270-277

  Xin, Zhixiang ^a   Huang, Yiran ^a   Lu, Jun ^b   Zhang, Qi ^b   Chen, Chen ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE;

CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; META ANALYSIS; MICTURITION; PRIORITY JOURNAL; RESIDUAL VOLUME; REVIEW; URINARY URGENCY; URODYNAMICS; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIMUTAGENIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; PROSTATISM;

EID: 84880894318     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.04.045     Document Type: Review

References (49)

1. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society Urology 61 2003 37 49
2. R. Rosen, J. Altwein, and P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 44 2003 637 649
3. S.O. Andersson, B. Rashidkhani, and L. Karlberg Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men BJU Int 94 2004 327 331
4. D.E. Irwin, I. Milsom, and S. Hunskaar Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol 50 2006 1306 1314 [discussion: 1314-1315]
5. M.H. Braun, F. Sommer, and G. Haupt Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey" Eur Urol 44 2003 588 594
6. P. Trueman, S.C. Hood, U.S. Nayak, and M.F. Mrazek Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK BJU Int 83 1999 410 415
7. G. Welch, K. Weinger, and M.J. Barry Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study Urology 59 2002 245 250
8. J.E. Batista-Miranda, B. Molinuevo, and Y. Pardo Impact of lower urinary tract symptoms on quality of life using Functional Assessment Cancer Therapy scale Urology 69 2007 285 288
9. K.T. McVary, C.G. Roehrborn, and A.L. Avins Update on AUA guideline on the management of benign prostatic hyperplasia J Urol 185 2011 1793 1803
10. J.Y. Lee, H.W. Kim, and S.J. Lee Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder BJU Int 94 2004 817 820
11. H. Saito, T. Yamada, and H. Oshima A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence Jpn J Urol Surg 12 1999 525 536
12. A. Athanasopoulos, K. Gyftopoulos, and K. Giannitsas Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study J Urol 169 2003 2253 2256
13. S.A. Kaplan, C.G. Roehrborn, and E.S. Rovner Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JAMA 296 2006 2319 2328
14. S.A. MacDiarmid, K.M. Peters, and A. Chen Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study Mayo Clin Proc 83 2008 1002 1010
15. S.A. Kaplan, K. McCammon, and R. Fincher Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency J Urol 182 2009 2825 2830
16. S.A. Kaplan, C.G. Roehrborn, and J. Gong Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms BJU Int 109 2012 1831 1840
17. A. Athanasopoulos, and P. Perimenis Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction Expert Opin Pharmacother 6 2005 2429 2433
18. R. Dmochowski Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? Curr Urol Rep 7 2006 462 467
19. G. Novara, A. Galfano, V. Ficarra, and W. Artibani Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review Eur Urol 50 2006 675 683
20. A. Athanasopoulos, D. Mitropoulos, K. Giannitsas, and P. Perimenis Safety of anticholinergics in patients with benign prostatic hyperplasia Expert Opin Drug Saf 7 2008 473 479
21. S.A. MacDiarmid Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia Curr Urol Rep 9 2008 265 271
22. S.A. Kaplan, C.G. Roehrborn, and P. Abrams Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review Int J Clin Pract 65 2011 487 507
23. A. Athanasopoulos, C. Chapple, and C. Fowler The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update Eur Urol 60 2011 94 105
24. W.H. Park, and H. Gon Kim Low-dose anticholinergic combination therapy in male benign prostatic hyperplasia patients with overactive bladder symptoms Low Urin Tract Symptoms 4 suppl s1 2012 102 109
25. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available at: www.cochrane-handbook.org. Accessed September 3, 2012.
26. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
27. K.S. Lee, M.S. Choo, and D.Y. Kim Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study J Urol 174 4 Pt 1 2005 1334 1338
28. O. Maruyama, Y. Kawachi, and K. Hanazawa Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study Int J Urol 13 2006 1280 1285
29. Y. Yang, X.F. Zhao, and H.Z. Li Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study Chin Med J (Engl) 120 2007 370 374
30. T. Yokoyama, K. Uematsu, and T. Watanabe Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study Scand J Urol Nephrol 43 2009 307 314
31. C. Chapple, S. Herschorn, and P. Abrams Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers Eur Urol 56 2009 534 541
32. O. Nishizawa, O. Yamaguchi, and M. Takeda Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics Low Urin Tract Symptoms 3 2011 29 35
33. O. Yamaguchi, H. Kakizaki, and Y. Homma Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms-ASSIST, randomized controlled study Urology 78 2011 126 133
34. S.H. Lee, B.H. Chung, and S.J. Kim Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study Prostate Cancer Prostatic Dis 14 2011 320 325
35. S.-D. Chung, H.C. Chang, and B. Chiu The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia Neurourol Urodyn 30 2011 568 571
36. C. Konstantinidis, M. Samarinas, and S. Andreadakis Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin-a prospective study Urol Int 90 2013 156 160
37. B.T. Blake-James, A. Rashidian, Y. Ikeda, and M. Emberton The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis BJU Int 99 2007 85 96
38. E. Colli, F. Parazzini, and L. Olivieri Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials Eur Urol 52 2007 525 530
39. J.B. Meigs, M.J. Barry, and E. Giovannucci Incidence rates and risk factors for acute urinary retention: the health professionals followup study J Urol 162 1999 376 382
40. C.G. Roehrborn, J.D. McConnell, and M. Lieber Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group Urology 53 1999 473 480
41. M.J. Marberger, J.T. Andersen, and J.C. Nickel Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials Eur Urol 38 2000 563 568
42. P. Abrams, S. Kaplan, H.J. De Koning Gans, and R. Millard Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction J Urol 175 3 Pt 1 2006 999 1004
43. S.A. Kaplan, W. He, and W.D. Koltun Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial Eur Urol 63 2013 158 165
44. J.Q. Clemens The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder Neurourol Urodyn 28 2009 727
45. C.G. Roehrborn, S.A. Kaplan, and S.R. Kraus Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB Urology 72 2008 1061 1067 [discussion: 1067]
46. C.G. Roehrborn, S.A. Kaplan, and J.S. Jones Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size Eur Urol 55 2009 472 479
47. C.R. Chapple, S. Herschorn, and P. Abrams Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration BJU Int 106 2010 1332 1338
48. K.E. Andersson Antimuscarinic mechanisms and the overactive detrusor: an update Eur Urol 59 2011 377 386
49. S.A. MacDiarmid Overactive bladder: improving the efficacy of anticholinergics by dose escalation Curr Urol Rep 4 2003 446 451